Drug Trial Radar · NCT07005102
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
854
Planned (sponsor's estimate)
Start
Aug 3, 2025
Primary completion
Nov 2036
Study completion Nov 2036
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 groups called treatment arms where 3 groups will receive 1 of 3 doses of telisotuzumab adizutecan from from the dose escalation phase with Osi, or standard of care (Osi plus chemotherapy). In the second stage participants will receive the optimal dose of telisotuzumab adizutecan, from the previous stage, with Osi, or SOC. Approximately 854 adult participants with 1L estimated glomerular filtration rate (EGFR) mut (mutated) not sufficient quantity (NSq) NSCLC will be enrolled in the study in 200 sites worldwide. In Stage 1, during dose escalation participants will receive increasing intravenous (IV) doses of telisotuzumab adizutecan with oral Osi tablets. participants will receive 1 of 3 doses of telisotuzumab adizutecan with Osi, or standard of care (Osi plus chemotherapy). In stage 2 participants will receive the optimal dose of IV telisotuzumab adizutecanin with oral Osi tablet, or SOC. The study will run for a duration of approximately 76 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- c-MET
Interventions
Standard of CareDrug
Standard of Care
Telisotuzumab AdizutecanDrug
Intravenous (IV)
Osimertinib (Osi)Drug
Oral
CisplatinDrug
IV
CarboplatinDrug
IV
PemetrexedDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to Approximately 76 Months
- Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.Time frame: Up to Approximately 76 Months
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 76 Months
Locations
65 sites in 13 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers - Chandler /ID# 275443
Chandler, Arizona · Recruiting
City of Hope National Medical Center /ID# 282241
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734
Irvine, California · Recruiting
USC Norris Comprehensive Cancer Center /ID# 275343
Los Angeles, California · Recruiting
Usc Norris Oncology/Hematology Treatment Center /ID# 278673
Newport Beach, California · Recruiting
UCLA - Santa Monica /ID# 276816
Santa Monica, California · Recruiting
City Of Hope - Upland /ID# 284650
Upland, California · Recruiting
University Colorado Cancer Center /ID# 275382
Aurora, Colorado · Recruiting
Mid Florida Hematology And Oncology Center /ID# 275278
Orange City, Florida · Recruiting
Kaiser Permanente Moanalua Medical Center /ID# 275942
Honolulu, Hawaii · Recruiting
The Iowa Clinic /ID# 276020
West Des Moines, Iowa · Completed
Nho - Revive Research Institute /ID# 276115
Lincoln, Nebraska · Recruiting
Renown Regional Medical Center /ID# 276049
Reno, Nevada · Recruiting
Texas Oncology - South Austin /ID# 276033
Austin, Texas · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 275107
Houston, Texas · Recruiting
Texas Oncology - Palestine Cancer Center /ID# 276034
Palestine, Texas · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 275071
Fairfax, Virginia · Recruiting
University of Washington Medical Center /ID# 275866
Seattle, Washington · Recruiting
Liverpool Hospital /ID# 276304
Liverpool, New South Wales, Australia · Recruiting
The Queen Elizabeth Hospital /ID# 275719
Woodville South, South Australia, Australia · Recruiting
Austin Health /ID# 275505
Heidelberg, Victoria, Australia · Recruiting
St John of God Murdoch Hospital /ID# 275700
Murdoch, Western Australia, Australia · Recruiting
CHU de Liege /ID# 277971
Liège, Belgium · Recruiting
Jessa Ziekenhuis - Campus Virga Jesse /ID# 275585
Hasselt, Limburg, Belgium · Recruiting
Universitair Ziekenhuis Leuven /ID# 275586
Leuven, Vlaams-Brabant, Belgium · Recruiting
AZ-Delta. /ID# 275753
Roeselare, West-Vlaanderen, Belgium · Recruiting
The Ottawa Hospital - General Campus /ID# 275611
Ottawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre /ID# 274845
Toronto, Ontario, Canada · Active not recruiting
Cancer Hospital - Chinese Academy of Medical Sciences /ID# 275631
Beijing, Beijing Municipality, China · Recruiting
Fujian Province Cancer Hospital /ID# 274913
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital Of Guangzhou Medical University /ID# 274914
Guangzhou, Guangdong, China · Recruiting
Union Hospital Tongji Medical College /ID# 278711
Wuhan, Hubei, China · Recruiting
The First affiliated hospital of Nanchang University /ID# 275257
Nanchang, Jiangxi, China · Recruiting
Shanghai Chest Hospital /ID# 275273
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University /ID# 274946
Chengdu, Sichuan, China · Recruiting
Rambam Health Care Campus- Haifa /ID# 274542
Haifa, Israel · Recruiting
Rabin Medical Center. /ID# 274540
Petah Tikva, Central District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 274541
Ramat Gan, Tel Aviv, Israel · Recruiting
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 277808
Perugia, Italy · Recruiting
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 280103
Roma, Italy · Recruiting
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.